Celcuity Inc. Schedules Release of Second Quarter 2020 Financial Results and Conference Call

MINNEAPOLIS, MN / ACCESSWIRE / July 24, 2020 / Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering diagnostics and expanded therapeutic options for cancer patients, announced that it will release its financial results for the second quarter 2020 after the stock market close on Monday, August 10, 2020. Management will host a teleconference the same day at 4:30 p.m. Eastern Time (ET) to discuss the results.

Conference Call Details

Participants should dial 1-866-342-8588 and use passcode 52638. Participants are asked to dial in 5 to 10 minutes prior to the start of the call.

About Celcuity

Celcuity is a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering companion diagnostics and expanded therapeutic options for cancer patients. Celcuity’s proprietary CELsignia diagnostic platform analyzes living tumor cells to untangle the complexity of the cellular activity driving a patient’s cancer. This allows Celcuity to discover new cancer sub-types molecular diagnostics cannot detect. We are driven to improve outcomes for patients and to transform how pharmaceutical companies define the patient populations for their targeted therapies. Celcuity is headquartered in Minneapolis, MN. Further information about Celcuity can be found at www.celcuity.com

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including the anticipated benefits to the clinical outcomes of cancer patients. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Celcuity, which include, but are not limited to, those set forth in the Risk Factors section of Celcuity’s Annual Report on Form 10-K for the year ended December 31, 2019. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Celcuity undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contacts:

Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
LifeSci Advisors, LLC
Jeremy Feffer, Jeremy@LifeSciAdvisors.com

SOURCE: Celcuity Inc.

View source version on accesswire.com:
https://www.accesswire.com/598838/Celcuity-Inc-Schedules-Release-of-Second-Quarter-2020-Financial-Results-and-Conference-Call

Staff

Recent Posts

How Luciana Preger Is Helping Advance Gilead’s Work in Oncology

NORTHAMPTON, MA / ACCESSWIRE / June 12, 2024 / Gilead SciencesLuciana Preger credits being exposed…

2 mins ago

Clearstep Unveils Advanced Self-Service Booking for Specialist Care

New AI-driven technology integration marks a first in the U.S., enhancing patient access to specialized…

2 mins ago

Rutherrin(R) Increases Efficacy of Chemotherapy

TORONTO, ON / ACCESSWIRE / June 12, 2024 / Theralase® Technologies Inc. ("Theralase®" or the…

2 mins ago

Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Targeted protein degradation (TPD*) technologies have demonstrated the potential to produce novel treatment approaches Surrozen’s…

3 mins ago